Using Electronic Patient-Reported Outcome Measures for Patients With Metastatic Renal Cell Carcinoma: A Narrative Review.

BACKGROUND

The variety of therapeutic associations in first-line treatment of advanced and metastatic renal cell cancer (mRCC) illustrates the complexity of toxicity management that can affect patients' health-related quality of life (HRQOL). Electronic monitoring applications have become part of the daily practice of providers in following up with people with cancer.

OBJECTIVES

This article offers perspectives for electronic patient-reported outcome measures (ePROMs) in clinical practice to enhance symptom management and HRQOL for patients with mRCC.

METHODS

A narrative review combines the results of searches conducted on MEDLINE®, Embase®, and Cochrane Library for articles that identify therapeutic combinations used in treating mRCC, extract HRQOL data, and evaluate the benefits of ePROMs.

FINDINGS: ePROMs can be adapted to the toxicity and symptom specificities encountered in patients with mRCC undergoing front-line treatment. Combined with multidimensional HRQOL indicators, these tools can improve symptom management and provide early support adapted to the patient's needs.